You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Requip & Adartrel (Ropinirole) artwork change

As a result of changes in the manufacturing process, and to standardise and harmonise the colours of the various strengths of Requip and Adartrel across different markets, there will be changes to the colour of the ink on both the cartons and blister packs of Requip and a blister pack of Adartrel. Whilst there is no impact on the medicine itself, GSK would like to draw this to your attention and encourage you to highlight the changes to your patients at the point of dispensing, particularly as some new colours were previously associated with different strengths.

By highlighting and educating patients at the point of dispensing, any potential medication errors, and any possible confusion to patients should be mitigated.

The below changes to colours will apply to blister packs, and in addition, the colours of the various cartons have been modified to match the blister pack. These changes have been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA).

In the UK this action will result in blisters colour changes outlined in the table below:

Product

Ink Colour OLD (UK)

Ink Colour NEW (UK)

ReQuip Tablets 0.25mg

Blue

Cyan

ReQuip Tablets 1mg

Yellow

Black

ReQuip Tablets 2mg

Cyan

Red

ReQuip Tablets 5mg

Black

Blue

Adartrel 0.5mg film coated-tablets

Yellow

Black

The approximate dates that the new presentations with updated colours should be in circulation are as follows:

Dates are subject to change

Product

Approximate date to market

(in chronological order)

Adartrel 0.5mg film coated-tablets

01-Jun-20

ReQuip Tablets 2mg

29-Jun-20

ReQuip Tablets 1mg

10-Aug-20

ReQuip Tablets 0.25mg

19-Oct-20

ReQuip Tablets 5mg

18-Jan-21

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow card in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.